Table 2.

Overall and CVD mortality among a population-based sample of breast cancer survivors and women without breast cancer stratified by time since the beginning of follow-up. The Long Island Breast Cancer Study Project, 1996-2009.

	Overall Mortality
	HR^a (95% CI)
Time since beginning of follow-up	Women without Breast Cancer (235 deaths)	Breast Cancer Survivors (407 deaths)	p^b
0-6 years	1.0	2.2 (1.7, 2.8)	0.04
>6 years	1.0	1.5 (1.3, 1.9)

	CVD Mortality
Time since beginning of follow-up	Women without Breast Cancer (114 deaths)	Breast Cancer Survivors (155 deaths)

	Cause-specific HR^a,^c (95% CI)		p^b
0-7 years	1.0	0.80 (0.53, 1.2)	0.004
>7 years	1.0	1.8 (1.3, 2.5)
	Subdistribution HR^a,^d (95% CI)		p^b
0-7 years	1.0	0.59 (0.40, 0.87)	<0.001
>7 years	1.0	1.9 (1.4, 2.7)

Models adjusted for age at reference date (date of diagnosis for breast cancer survivors and date of identification for women without breast cancer), menopausal status, previous use of hormone replacement therapy, smoking history, average lifetime alcohol intake, body mass index the year before reference date, income, education, and history of the following cardiovascular disease risk factors: diabetes, myocardial infarction, hypertension, dyslipidemia or stroke. Model for overall mortality included interaction between follow-up time and history of hypertension and myocardial infarction and models for CVD mortality included interaction between follow-up time and history of diabetes.

P-value for likelihood ratio test of interaction between breast cancer status and time.

Cause-specific hazard ratio estimates relative rate of CVD mortality between women with and without breast cancer, not accounting for competing causes of death.

Subdistribution hazard ratio reflects association between breast cancer diagnosis and incidence of CVD death.